Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors
Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors
复制标题
DOI：
10.1111/j.1399-0039.2006.759_2.x
复制
发表时间：
2007-04-01
期刊：
影响因子：
--
通讯作者：
Horowitz, M.
中科院分区：
文献类型：
--
作者：
Petersdorf, E. W.;Gooley, T.;Horowitz, M.
如果人类白细胞抗原（HLA）差异不会导致发病率和死亡率增加，则可以通过使用不匹配的供体来扩大无关供体造血细胞移植的应用。管理HLA错配的允许性的规则没有很好地定义。国际造血细胞移植组织相容性工作组测量了4796例因低、中、高危血液病接受移植的患者中与基因座特异性差异相关的风险。给定HLA错配的允许性部分地由基因座和疾病风险定义。
The application of unrelated donor hematopoietic cell transplantation can be expanded with the use of mismatched donors if human leukocyte antigen (HLA) disparity does not lead to increased morbidity and mortality. The rules that govern permissibility of HLA mismatches are not well defined. The International Histocompatibility Working Group in hematopoietic cell transplantation measured the risks associated with locus-specific disparity in 4796 patients transplanted for low, intermediate, or high-risk hematologic diseases. The permissibility of a given HLA mismatch is in part defined by the locus and by disease risk.